|
gptkbp:instanceOf
|
gptkb:drug
antidepressant
selective serotonin reuptake inhibitor
|
|
gptkbp:approvalYear
|
1987
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:N06AB03
|
|
gptkbp:brand
|
gptkb:Prozac
gptkb:Rapiflux
gptkb:Sarafem
Selfemra
|
|
gptkbp:canCauseWithdrawal
|
yes
|
|
gptkbp:CASNumber
|
54910-89-3
|
|
gptkbp:contraindication
|
concurrent use with MAO inhibitors
hypersensitivity to fluoxetine
|
|
gptkbp:discoveredBy
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:eliminationHalfLife
|
1 to 3 days (parent drug)
7 to 15 days (active metabolite)
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:genericName
|
yes
|
|
gptkbp:hasMolecularFormula
|
C17H18F3NO
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Fluoxetine
|
|
gptkbp:interactsWith
|
gptkb:beer
gptkb:tricyclic_antidepressants
gptkb:phenytoin
gptkb:warfarin
gptkb:MAO_inhibitors
gptkb:benzodiazepines
gptkb:NSAIDs
gptkb:carbamazepine
lithium
antipsychotics
other serotonergic drugs
|
|
gptkbp:IUPACName
|
gptkb:N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine
|
|
gptkbp:KEGGID
|
gptkb:D00544
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits reuptake of serotonin
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:patentExpired
|
2001
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
94.5%
|
|
gptkbp:PubChem_CID
|
3269
CHEMBL27
3386
DB00472
|
|
gptkbp:riskOfSerotoninSyndrome
|
yes
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
anxiety
headache
loss of appetite
sweating
insomnia
dry mouth
sexual dysfunction
|
|
gptkbp:UNII
|
01K63SUP8D
|
|
gptkbp:usedFor
|
gptkb:obsessive-compulsive_disorder
gptkb:panic_disorder
gptkb:major_depressive_disorder
gptkb:bulimia_nervosa
premenstrual dysphoric disorder
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Antidepressants
|
|
gptkbp:bfsLayer
|
6
|